EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Safety and Efficacy of Nerandomilast in Patients With Pulmonary Fibrosis: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials

Humna Shahzad, Usama Afzaal, Fahad Saleem, Ahmad Hassan Gul, Freya Thummar, Hafiz Nadir Murtaza, Abel Gelan, Maria Ahsan, Rafay Irfan, Ahmad Nawaz, Uzair Jafar, Asma'a Munasar Ali Alsubari iD und 4 weitere

The Clinical Respiratory Journal · 2026-03 · 20 (3)

DOI: 10.1111/crj.70181 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift The Clinical Respiratory Journal, online erschienen am 11.03.2026. Verfasst von Humna Shahzad und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Nishtar Medical University, Multan, Pakistan. Hauptthemen laut MEDLINE: Pulmonary Fibrosis, Phosphodiesterase 4 Inhibitors. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Nerandomilast, an oral phosphodiesterase‐4 (PDE4) inhibitor, has shown potential in slowing the progression of pulmonary fibrosis. This meta‐analysis evaluated the efficacy and safety of nerandomilast in preserving lung function among patients with pulmonary fibrosis.

Methods

MEDLINE, Embase, the Cochrane Library, and ClinicalTrials.gov were systematically searched for randomized controlled trials (RCTs) comparing nerandomilast with placebo. Study quality was assessed using the Cochrane Risk of Bias 2.0 tool. Analyses were performed in RevMan 5.4 using random‐effects models with risk ratios (RR) and mean differences (MD) as effect measures.

Results

Four RCTs ( n = 2515) were included. Nerandomilast significantly attenuated the decline in forced vital capacity (FVC) compared with placebo (MD: 69.25 mL, 95% CI: 52.1–86.29), but did not improve diffusing capacity for carbon monoxide (DLCO) (MD: 0.84, 95% CI: −0.56 to 2.24). It was associated with a lower pooled risk of all‐cause mortality (RR: 0.68, 95% CI: 0.52–0.88) without increasing adverse events (RR: 1.00, 95% CI: 0.98–1.02) or serious adverse events (RR: 0.93, 95% CI: 0.76–1.14).

Conclusion

Nerandomilast appears to slow lung function decline in pulmonary fibrosis without added safety risks. Although a lower pooled risk of mortality was observed, individual trials were not powered for mortality outcomes, and event rates were low; therefore, this finding should be interpreted cautiously. Given the heterogeneity of pulmonary fibrosis phenotypes and trial designs, further large‐scale RCTs should explore standardized outcomes, subgroup effects, and combination strategies with nintedanib or pirfenidone.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pulmonary FibrosisPhosphodiesterase 4 InhibitorsHumansRandomized Controlled Trials as TopicTreatment OutcomeVital CapacityDisease ProgressionRespiratory Function TestsCyclobutanesPiperidines

Stichwörter der Autor:innen

IPFPDE4 inhibitorsmeta‐analysisnerandomilastpulmonary fibrosis

Substanzen

Phosphodiesterase 4 InhibitorsnerandomilastCyclobutanesPiperidines

Autor:innen und Institutionen

  • Department of Medicine, Nishtar Medical University, Multan, Pakistan.
  • Department of Internal Medicine, Baptist Hospitals of Southeast Texas, Beaumont, Texas, USA.
  • Department of Medicine, Punjab Medical College, Faisalabad, Pakistan.
  • Department of Medicine, C. U. Shah Medical College, Surendranagar, India.
  • Department of Medicine, King Edward Medical University, Lahore, Pakistan.
  • Department of Public Health, Tulane University, Louisiana, USA.

ORCID-Profile: Asma'a Munasar Ali Alsubari, Muhammad Ehsan

Zitieren

APA

Shahzad, H., Afzaal, U., Saleem, F., Gul, A. H., Thummar, F., Murtaza, H. N., Gelan, A., Ahsan, M., Irfan, R., Nawaz, A., Jafar, U., Alsubari, A. M. A., Ehsan, M., Nadeem, A., Komminni, P. K., & Iribarren, J. (2026). Safety and Efficacy of Nerandomilast in Patients With Pulmonary Fibrosis: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials. The Clinical Respiratory Journal, 20(3). https://doi.org/10.1111/crj.70181

Vancouver

Shahzad H, Afzaal U, Saleem F, Gul AH, Thummar F, Murtaza HN, et al. Safety and Efficacy of Nerandomilast in Patients With Pulmonary Fibrosis: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials. The Clinical Respiratory Journal. 2026;20(3). doi:10.1111/crj.70181

BibTeX
@article{Shahzad2026,
  author = {Shahzad, Humna and Afzaal, Usama and Saleem, Fahad and Gul, Ahmad Hassan and Thummar, Freya and Murtaza, Hafiz Nadir and Gelan, Abel and Ahsan, Maria and Irfan, Rafay and Nawaz, Ahmad and Jafar, Uzair and Alsubari, Asma'a Munasar Ali and Ehsan, Muhammad and Nadeem, Ahmed and Komminni, Praveen Kumar and Iribarren, Juan},
  title = {Safety and Efficacy of Nerandomilast in Patients With Pulmonary Fibrosis: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials},
  journal = {The Clinical Respiratory Journal},
  year = {2026},
  volume = {20},
  number = {3},
  doi = {10.1111/crj.70181}
}
Kostenlos starten →